### TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 7-21-97 AND 8-1-97—Continued

Name of acquiring person, name of acquired person, name of acquired entity		Date terminated
Henry Schein, Inc., Marvin Sandler, IDE Interstate, Inc	97–2879	07/28/97
Schering-Plough Corporation, Acutek Adhesive Specialties, Inc., Acutek Adhesive Specialties, Inc.	97–2881	07/28/97
William J. Kidd, Bruce Fleisher, Pilot Technologies Corp	97–2884	07/28/97
William J. Kidd, Hennessy Products Incorporated, Hennessy Products Incorporated	97–2885	07/28/97
Robert Hess, United States Surgical Corporation, United States Surgical Corporation	97–2886	07/28/97
Church & Dwight Co., Inc., Dial Corporation (The), Dial Corporation (The)	97–2888	07/28/97
Philip Services Corporation, Intermetco Limited, Intermetco Limited	97–2891	07/28/97
Electronic Manufacturing Systems, Inc., Michael and Suzanne Moshier, Talus Corporation	97–2893	07/28/97
Omnicom Group Inc., John D. Graham, Fleishman-Hillard, Inc.	97–2894	07/28/97
Cornerstone Equity Investors IV, L.P., Interim Service Inc., Interim Healthcare Inc./Interim Healthcare of NY,	07 2001	01/20/01
Inc	97-2895	07/28/97
Physician Sales & Service, Inc., S&W X-Ray, Inc., S&W X-Ray, Inc	97-2896	07/28/97
VEBA AG, Wyle Electronics, Wyle Electronics	97-2900	07/28/97
Morgan Stanley Real Estate Fund II, L.P. (The), George P. Mitchell, The Woodlands Corporation	97-2912	07/28/97
Rodale Press, Inc., K-III Communications Corporation, K-III Magazine Corporation	97-2917	07/28/97
Republic Industries, Inc., Robert W. Navarre, II, Libertyville Enterprises, Inc.	97-2921	07/28/97
Robert W. Navarre, II, Republic Enterprises, Inc., Republic Enterprises, Inc.	97-2922	07/28/97
Jonathan O. Lee, Novartis AG, Novartis Consumer Health, Inc	97-2928	07/28/97
FrontierVision Partners, L.P., Gus Constantin and Mary Jane Constantin, PCI One, Incorporated	97-2634	07/29/97
Seagate Technology, Inc., Quinta Corporation, Quinta Corporation	97–2711	07/29/97
Gordon Crawford, CheckFree Corporation, Servantis Systems, Inc	97-2720	07/29/97
Conseco, Inc., Leucadia National Corporation, Colonial Penn Life Insurance Co., Providential Life	97–2799	07/29/97
American Home Products Corporation, Pharmacia & Upjohn, Inc., Pharmacia & Upjohn AB	97-2805	07/29/97
Sprint Corporation, Michael H. Holthouse, Paranet, Inc	97-2914	07/29/97
Eric A. Rothfeld, Miles Rubin, Sun Apparel, Inc., Import Technology of Texas, Inc	97-2929	07/29/97
Corporate Express, Inc., David R. McShane, McShane Enterprise, Inc.	97-2783	07/30/97
Genicom Corporation, Digital Equipment Corporation, Digital Equipment Corporation	97-2923	07/30/97
Barclay McFadden, United Natural Foods, Inc., United Natural Foods, Inc.	97–2772	07/31/97
Richard S. Youngman, United Natural Foods, Inc., United Natural Foods, Inc.	97–2773	07/31/97
United Natural Foods, Inc., Barclay McFadden, Stow Mills, Inc	97–2774	07/31/97
United Natural Foods, Inc., Richard S. Youngman, Stow Mills, Inc	97–2775	07/31/97
Laidlaw Inc., CMS Mid-Atlantic Business Opportunity Partners, L.P., The DAVE Companies Inc	97–2781	07/31/97
Culp, Inc., S. Davis Phillips, Phillips Weaving Mills, Inc., Phillips Printing	97–2782	07/31/97
21st Century Newspapers Acquisition, Inc., Walt Disney Company (The), Great Lakes Media, Inc	97–2821	07/31/97
Hawk Corporation, Robert G. Sierks, Sinterloy, Inc	97–2825	07/31/97
Harold Sargeant, Sr., Koch Industries, Inc., Koch Industries, Inc.	97–2295	08/01/97
Marinya Holdings Pty. Ltd., The Walt Disney Company, Farm Progress Holding Company, Inc	97–2829	08/01/97
Spacelabs Medical, Inc., Burdick, Inc., Burdick, Inc.	97–2843	08/01/97
David C. McCourt, WorldCom, Inc., WorldCom, Inc.	97–2864	08/01/97
Gulf Polymer and Petrochemical, Inc., B.F. Goodrich Company, (The), B.F. Goodrich Company, (The)	97–2908	08/01/97
Whole Foods Market, Inc., Amrion, Inc., Amrion, Inc.	97–2916	08/01/97
Joseph M. Field, Louis J. Appell Residuary Trust, KTHX License Investment Co. and KTHX Radio Inc	97–2930	08/01/97
Mr. John K. Castle, Vickers PLC, a U.K. Corporation, Jered Brown Brothers, Inc	97–2933	08/01/97
Authentic Specialty Foods, Inc., TSG2 L.P., La Victoria Foods, Inc.	97–2940	08/01/97
Additional Specialty (See a), 1882 Early, La Violente (See a), 110	37 2040	00/01/01

#### FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room 303, Washington, DC 20580, (202) 326–3100.

By direction of the Commission.

#### Benjamin I. Berman,

Acting Secretary.
[FR Doc. 97–22490 Filed 8–22–97; 8:45 am]
BILLING CODE 6750–01–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of National AIDS Policy; Notice of Meeting of the Presidential Advisory Council on HIV/AIDS and Its Subcommittees

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Presidential Advisory Council on HIV/AIDS on December 4–7, 1997, at the Omni Shoreham Hotel, Washington, DC. The meeting of the Presidential Advisory Council on HIV/AIDS will take place on Thursday, December 4, Friday, December 5, Saturday, December 6, and Sunday, December 7 from 8:30 am to 5:30 pm at the Omni Shoreham Hotel, 2500 Calvert St., NW, Washington, DC 20008. The meetings will be open to the public.

The purpose of the subcommittee meetings will be to assess the Administration's response to previous recommendations and assess the status of previous recommendations made to the Administration. The agenda of the Presidential Advisory Council on HIV/AIDS may include presentations from the Council's seven committees, Research, Services, Prevention, International, Discrimination, Communities for African and Latino Descent, and Prison Issues.

Daniel C. Montoya, Executive Director, Presidential Advisory Council on HIV and AIDS, Office of National AIDS Policy, 808 17th Street, N.W., Suite 820, Washington, D.C. 20006, Phone (202) 632–1090, Fax (202) 632– 1096, will furnish the meeting agenda and roster of committee members upon request. Any individual who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ann Borlo at (301) 986–4870 no later than November 1, 1997.

Dated: August 19, 1997.

#### Daniel C. Montoya,

Executive Director, Presidential Advisory Council on HIV and AIDS, Office of National AIDS Policy.

[FR Doc. 97–22533 Filed 8–22–97; 8:45 am] BILLING CODE 3195–01–M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **Administration on Aging**

Agency Recordkeeping/Reporting Requirements Under Emergency Review by the Office of Management and Budget (OMB)

The Department of Health and Human Services has submitted the following (see below) emergency processing public information clearance request (ICR) to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (P.L. 104–13, 44 U.S.C. Chapter 35).

*Title:* State Annual Long-Term Care Ombudsman Report.

OMB Number: 0985-0005.

Instrument	Number of respondents	Number of responses per year	Average burden hours per respondent	Total bur- den hours
State Annual Long-Term Care Ombudsman Report.	52 State Agencies on Aging	Once per respondent per year	173	9,000

Description: To revise an existing information collection for States to use in reporting on activities of their Long-Term Care Ombudsman Programs as required under Section 712(b) and (h) of the Older Americans Act, as amended; the revisions:

- (1) Modify the wording of some of the complaint categories to assist respondents in categorizing some complaints which were being placed under "other;" and
- (2) Stipulate that several narrative responses which have not changed since the previous report do not need to be repeated.

The reporting system is for fiscal year 1997–99.

Additional Information: The AoA is requesting that OMB grant a 180-day approval for this information collection under procedures for emergency processing by August 29, 1997. A copy of this individual ICR, with applicable supporting documentation, may be obtained by calling the Administration on Aging, Reports Clearance Officer, Sharon Matthews at (202) 205–2814.

Comments and questions about the ICR should be directed to the Office of Information and Regulatory Affairs, Attn: Allison Herron Eydt, OMB Desk Officer, Office of Management and Budget, Room 10325, Washington, DC 20503.

Dated: August 14, 1997.

#### Alicia Valadez Ors,

Director, Office of Governmental Affairs and Elder Rights, Administration on Aging.
[FR Doc. 97–22417 Filed 8–22–97; 8:45 am]
BILLING CODE 4150–04–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 91F-0032]

Th. Goldschmidt A.G.; Withdrawal of Food Additive Petition

**AGENCY:** Food and Drug Administration,

HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 1B4244) proposing that the food additive regulations be amended to provide for the safe use of silicone acrylate resins in coatings for metal substrates, polyolefin films, and paper and paperboard intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFS-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3091. **SUPPLEMENTARY INFORMATION:** In a notice published in the Federal Register of March 4, 1991 (56 FR 9012), FDA announced that a food additive petition (FAP 1B4244) had been filed by Th. Goldschmidt A.G. (currently c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001). The petition proposed to amend the food additive regulations to provide for the safe use of silicone acrylate resins for use in coatings for metal substrates, polyolefin films, and paper and paperboard intended for use in contact with food. Th. Goldschmidt A.G. has now withdrawn the petition without

prejudice to a future filing (21 CFR 171.7).

Dated: August 7, 1997.

#### Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition. [FR Doc. 97–22554 Filed 8–22–97; 8:45 am] BILLING CODE 4160–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D-0331]

Guidance for Industry on Dissolution Testing of Immediate Release Solid Oral Dosage Forms; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Dissolution Testing of Immediate Release Solid Oral Dosage Forms." The purpose of this guidance document is to provide general recommendations for dissolution testing, approaches for setting dissolution specifications related to biopharmaceutic characteristics of the drug substance, statistical methods for comparing dissolution profiles, and a process to help determine when dissolution testing is sufficient to grant a waiver for an in vivo bioequivalence study. This guidance document also provides recommendations for dissolution tests to help ensure continuous drug product quality and performance after certain postapproval manufacturing changes.